var data={"title":"Ruxolitinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ruxolitinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/489134?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ruxolitinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ruxolitinib: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13376660\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Jakafi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14732981\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Jakavi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374759\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Janus Associated Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Janus Associated Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382600\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consider gradually tapering off (by 5 mg twice daily each week) if discontinuing for reasons other than thrombocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Myelofibrosis:</b> Oral: Initial dose (based on platelet count, titrate dose thereafter based on efficacy and safety):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &gt;200,000/mm<sup>3</sup>: 20 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets 100,000 to 200,000/mm<sup>3</sup>: 15 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets 50,000 to &lt;100,000/mm<sup>3</sup>: 5 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage modification based on response in patients with baseline platelet count &ge;100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib:</b> For insufficient response (with adequate platelet and neutrophil counts), may increase the dose in 5 mg twice daily increments to a maximum dose of 25 mg twice daily. Do not increase during initial 4 weeks and no more frequently than every 2 weeks. Discontinue treatment after 6 months if no reduction in spleen size or no improvement in symptoms. When discontinuing for reasons other than thrombocytopenia, consider gradually tapering by ~5 mg twice daily per week.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose increases may be considered if meet all of the following situations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Failure to achieve either a 50% reduction (from baseline) in palpable spleen length or a 35% reduction (from baseline) in spleen volume (measured by CT or MRI)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Platelet count &gt;125,000/mm<sup>3</sup> at 4 weeks (and never &lt;100,000/mm<sup>3</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Absolute neutrophil count (ANC) &gt;750/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage modification for bleeding requiring intervention (regardless of platelet count):</b> Interrupt treatment until bleeding resolved; may consider resuming at the prior dose if the underlying cause of bleeding has resolved or at a reduced dose if the underlying cause of bleeding persists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage modification based on response in patients with baseline platelet 50,000 to &lt;100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib: US labeling: </b> For insufficient response (with adequate platelet and neutrophil counts), may increase the dose in 5 mg daily increments to a maximum dose of 10 mg twice daily. Do not increase during initial 4 weeks and no more frequently than every 2 weeks. Discontinue treatment after 6 months if no reduction in spleen size or no improvement in symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose increases may be considered if meet all of the following situations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Platelet count remains &ge;40,000/mm<sup>3</sup> and did not decrease more than 20% in prior 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Absolute neutrophil count (ANC) &gt;1,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- No adverse event or hematological toxicity resulting in dose reduction or interruption occurred in prior 4 weeks</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Polycythemia vera:</b> Oral: Initial dose: 10 mg twice daily (titrate dose based on efficacy and safety)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dose modification due to insufficient response:</b> If response is insufficient and platelet, hemoglobin, and neutrophil counts are adequate, the dose may be increased in 5 mg twice daily increments to a maximum of 25 mg twice daily, Do not increase dose in the first 4 weeks of treatment and not more frequently than every 2 weeks. Consider dose increases in patients who meet all of the following conditions:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Inadequate efficacy demonstrated by one or more of the following: Continued need for phlebotomy, WBC &gt;ULN of normal range, platelet count &gt;ULN of normal range, or palpable spleen that is reduced by &lt;25% from baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Platelet count &ge;140,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Hemoglobin &ge;12 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- ANC &ge;1,500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Dosage adjustment with concomitant strong CYP3A4 inhibitors and fluconazole (&le;200 mg):</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Avoid concomitant use with fluconazole doses &gt;200 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Myelofibrosis: Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &ge;100,000/mm<sup>3</sup>: 10 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets 50,000/mm<sup>3</sup> to &lt; 100,000/mm<sup>3</sup>: 5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monitor closely and further adjust dose based on safety and efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Polycythemia vera:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose (ruxolitinib na&iuml;ve): 5 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stabilized on ruxolitinib &ge;10 mg twice daily: Reduce dose by 50% (rounded up to the closest available tablet strength).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stabilized on ruxolitinib 5 mg twice daily: Reduce dose to 5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stabilized on ruxolitinib 5 mg once daily: Avoid strong CYP3A4 inhibitors or fluconazole or interrupt treatment for the duration of strong CYP3A4 inhibitor or fluconazole use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monitor closely and further adjust dose based on safety and efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382599\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelofibrosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 59 mL/minute and platelets &gt;150,000/mm<sup>3</sup>: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 59 mL/minute and platelets 100,000 to 150,000/mm<sup>3</sup>: Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 59 mL/minute and platelets 50,000 to &lt;100,000/mm<sup>3</sup>: Initial dose: 5 mg once daily; additional dose adjustments should be made with careful monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 59 mL/minute and platelets &lt;50,000/mm<sup>3</sup>: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on dialysis and platelets 100,000 to 200,000/mm<sup>3</sup>: Initial dose: 15 mg once after dialysis; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with frequent monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD on dialysis and platelets &gt;200,000/mm<sup>3</sup>: Initial dose: 20 mg once after dialysis; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with frequent monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD not requiring dialysis: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polycythemia vera:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 59 mL/minute and any platelet count: Initial: 5 mg twice daily. Additional dose adjustments should be made with frequent monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on dialysis: Initial dose: 10 mg once after dialysis; additional dose adjustments should be made with careful monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD not requiring dialysis: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis is not expected to enhance the elimination of ruxolitinib.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382598\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelofibrosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets &gt;150,000/mm<sup>3</sup>: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets 100,000 to 150,000/mm<sup>3</sup>: Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets 50,000 to &lt;100,000/mm<sup>3</sup>: Initial dose: 5 mg once daily; additional dose adjustments should be made with careful monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets &lt;50,000/mm<sup>3</sup>: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polycythemia vera:</b> Mild to severe impairment (Child-Pugh class A, B, or C) and any platelet count: Initial dose: 5 mg twice daily; additional dose adjustments should be made with careful monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382628\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Myelofibrosis:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage modification for treatment interruption:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If baseline platelet count &ge;100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib and:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;50,000/mm<sup>3</sup> and ANC &lt;500/mm<sup>3</sup>: Interrupt treatment; upon platelet recovery (to &ge;50,000/mm<sup>3</sup>) or ANC recovery (to &ge;750/mm<sup>3</sup>), dosing may be restarted or increased based on the following platelet or ANC levels</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &ge;125,000/mm<sup>3</sup>: Dose should be at least 5 mg twice daily below the dose at treatment interruption, up to a maximum of 20 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets 100,000 to &lt;125,000/mm<sup>3</sup>: Dose should be at least 5 mg twice daily below the dose at treatment interruption, up to a maximum of 15 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets 75,000 to &lt;100,000/mm<sup>3</sup>: Dose should be at least 5 mg twice daily below the dose at treatment interruption, up to a maximum of 10 mg twice daily for at least 2 weeks; may increase to 15 mg twice daily if stable</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets 50,000 to &lt;75,000/mm<sup>3</sup>: 5 mg twice daily for at least 2 weeks; may increase to 10 mg twice daily if stable</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;50,000/mm<sup>3</sup>: Continue to withhold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &ge;750/mm<sup>3</sup>: Resume at 5 mg once daily or 5 mg twice daily below the largest dose in the week prior to treatment interruption, whichever is greater</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Long-term maintenance at 5 mg twice daily has not demonstrated responses; limit use of the dose level to patients where the benefits outweigh risks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If baseline platelet count 50,000 to &lt;100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib and:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;25,000/mm<sup>3</sup> and ANC &lt;500/mm<sup>3</sup>: Interrupt treatment; upon platelet recovery (to &ge;35,000/mm<sup>3</sup>) or ANC recovery (to &ge;750/mm<sup>3</sup>), resume at 5 mg once daily or 5 mg twice daily below the largest dose in the week prior to treatment interruption, whichever is greater</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Long-term maintenance at 5 mg twice daily has not demonstrated responses; limit use of the dose level to patients where the benefits outweigh risks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage reduction for thrombocytopenia in patients with baseline platelet count &ge;100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib: </b></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\"></th>\n          <th colspan=\"5\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dose at Time of Thrombocytopenia</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"6\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <b>Note:</b> Long-term maintenance at 5 mg twice daily has not demonstrated responses; limit use of the dose level to patients where the benefits outweigh risks</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg twice/day</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Platelet Count</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">New Dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">New Dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">New Dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">New Dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">New Dose</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100,000 to &lt;125,000/mm<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No change</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No change</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No change</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75,000 to &lt;100,000/mm<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No change</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No change</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50,000 to &lt;75,000/mm<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg twice/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No change</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;50,000/mm<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold dose</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold dose</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage reduction for thrombocytopenia in patients with baseline platelet 50,000 to &lt;100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets 25,000 to &lt;35,000/mm<sup>3</sup> <b> and</b> platelet count decreased &lt;20% during prior 4 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current daily dose &gt;5 mg: Reduce dose by 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current dose 5 mg once daily: Continue 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets 25,000 to &lt;35,000/mm<sup>3</sup> <b>and </b>platelet count decreased &ge;20% during prior four weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current daily dose &gt;10 mg: Reduce dose by 5 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current dose 5 mg twice daily: Reduce dose to 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If current dose 5 mg once daily: Continue 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &lt;25,000 mm<sup>3</sup>: Continue to withhold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Long-term maintenance at 5 mg twice daily has not demonstrated responses; limit use of the dose level to patients where the benefits outweigh risks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Polycythemia vera: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoglobin &ge;12 g/dL AND platelets &ge;100,000/mm<sup>3</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoglobin 10 to &lt;12 g/dL AND platelets 75,000 to &lt;100,000/mm<sup>3</sup>: Consider dosage adjustment to avoid dose interruptions due to anemia and thrombocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoglobin 8 to &lt;10 g/dL OR platelets 50,000 to &lt;75,000/mm<sup>3</sup>: Reduce dose by 5 mg twice daily; for patients currently receiving 5 mg twice daily, reduce dose to 5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoglobin &lt;8 g/dL OR platelets &lt;50,000/mm<sup>3</sup> OR ANC &lt;1,000/mm<sup>3</sup>: Interrupt dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <b>Dosage reduction following treatment interruption (use the most severe category of hemoglobin, platelets or ANC to determine reinitiation dose): </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemoglobin &lt;8 g/dL OR platelets &lt;50,000/mm<sup>3</sup> OR ANC &lt;1,000/mm<sup>3</sup>: Continue to hold.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemoglobin 8 to &lt;10 g/dL OR platelets 50,000 to &lt;75,000/mm<sup>3</sup> OR ANC 1,000 to &lt;1,500/mm<sup>3</sup>: Restart at a maximum of 5 mg twice daily (continue treatment for at least 2 weeks, if stable, then may increase dose by 5 mg twice daily) or no more than 5 mg twice daily less than the dose that resulted in dose interruption</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemoglobin 10 to &lt;12 g/dL OR platelets 75,000 to &lt;100,000/mm<sup>3</sup> OR ANC 1,500 to &lt;2,000/mm<sup>3</sup>: Restart at a maximum of 10 mg twice daily (continue treatment for at least 2 weeks, if stable, then may increase dose by 5 mg twice daily) or no more than 5 mg twice daily less than the dose that resulted in dose interruption</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemoglobin &ge;12 g/dL OR platelets &ge;100,000/mm<sup>3</sup> OR ANC &ge;2,000/mm<sup>3</sup>: Restart at a maximum of 15 mg twice daily (continue treatment for at least 2 weeks, if stable, then may increase dose by 5 mg twice daily) or no more than 5 mg twice daily less than the dose that resulted in dose interruption</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> If dose interruption was required while receiving 5 mg twice daily, may restart at 5 mg twice daily or 5 mg once daily (but not higher) once hemoglobin is &ge;10 g/dL, platelets are &ge;75,000/mm<sup>3</sup>, and ANC is &ge;1,500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <b>Dose management after restarting treatment:</b> After restarting following a dose interruption, the dose may be titrated, although the maximum total daily dose should not exceed 5 mg less than the dose resulting in the interruption (unless dose interruption following phlebotomy-associated anemia, in which case the maximum total daily dose is not limited).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13375647\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jakafi: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382561\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382560\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Available through specialty/network pharmacies. Further information may be obtained from the manufacturer, Incyte, at 1-855-452-5234 or at www.Jakafi.com. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382602\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered orally with or without food. If a dose is missed, return to the usual dosing schedule and do <b>not</b> administer an additional dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If unable to ingest tablets, may administer through a nasogastric (NG) tube (&ge;8 Fr): Suspend 1 tablet in ~40 mL water and stir for ~10 minutes and administer (within 6 hours after dispersion) with appropriate syringe; rinse NG tube with ~75 mL water (effect of enteral tube feeding on ruxolitinib exposure has not been evaluated)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132643\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (meets NIOSH 2016 criteria). This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Drugs are classified as hazardous based on their properties; the properties of a hazardous drug include one or more of the following characteristics: carcinogenic, teratogenic (or other developmental toxicity), reproductive toxicity, organotoxic at low doses, genotoxic, and/or new agents with structural or toxicity profiles similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374761\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelofibrosis:</b> Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polycythemia vera:</b> Treatment of polycythemia vera with an inadequate response to or intolerance to  hydroxyurea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382558\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ruxolitinib may be confused with PONATinib, regorafenib, riTUXimab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382579\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (15% to 18%), headache (15% to 16%), fatigue (15%), insomnia (12%) (Verstovsek 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Bruise (23%), pruritus (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum cholesterol (17% to 35%), hypertriglyceridemia (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (15%), abdominal pain (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (72% to 96%; grade 3: &le;34%; grade 4: &le;11%), thrombocytopenia (27% to 70%; grade 3: 5% to 9%; grade 4: &le;4%), neutropenia (3% to 19%; grade 3: 5%; grade 4: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (25%; grade 3: &lt;1%), increased serum AST (17% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (8%), hypertension (&lt;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (8%), nausea (6%), flatulence (5%), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&le;9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (2% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (9%), cough (8%), epistaxis (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Bradycardia, disseminated intravascular coagulation, fever, hemorrhagic diathesis, hypotension, multi-organ failure, myelofibrosis (symptom exacerbation), progressive multifocal leukoencephalopathy, prolonged Q-T interval on ECG, respiratory distress, systolic hypertension, tuberculosis, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382566\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to ruxolitinib or any component of the formulation or container; history of or current progressive multifocal leukoencephalopathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382567\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: Hematologic toxicity, including thrombocytopenia, anemia and neutropenia may occur; may require dosage modification. Monitor complete blood counts at baseline, every 2 to 4 weeks during dose stabilization, and then as clinically necessary. Thrombocytopenia is generally reversible with treatment interruption or dose reduction; platelet transfusions may be administered during treatment if clinically indicated. Anemia may require blood transfusion; may consider dose modification. Neutropenia (ANC &lt;500/mm<sup>3</sup>) is generally reversible and managed by treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Serious bacterial, mycobacterial (including tuberculosis), fungal, or viral infections have occurred. Active serious infections should be resolved prior to treatment initiation. Monitor for infections (including signs/symptoms of active tuberculosis and herpes zoster) during treatment. Prompt treatment is recommended if symptoms of active tuberculosis and/or herpes zoster infection develop. Evaluate for tuberculosis risk factors prior to treatment initiation; patients at higher risk for tuberculosis (prior residence/travel to countries with a high tuberculosis prevalence, close contacts with active tuberculosis, or history of latent or active tuberculosis where adequate treatment course cannot be confirmed) should be tested for latent infection. For patients with evidence of tuberculosis (active or latent), decide risk-benefit of continuing treatment. Progressive multifocal leukoencephalopathy (PML) has been reported; discontinue and evaluate if suspected. Hepatitis B viral load (HBV-DNA titer) increases (with and without associated ALT or AST elevations) have been reported with ruxolitinib in patients with chronic hepatitis B infection, although the effect of ruxolitinib is unknown; monitor and manage appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipid abnormalities: Ruxolitinib has been associated with increases in lipid parameters (eg, total cholesterol, LDL cholesterol, and triglycerides). Assess lipid parameters 8 to 12 weeks after ruxolitinib initiation; monitor and manage hyperlipidemia accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Non-melanoma skin cancer: Non-melanoma skin cancers (basal cell, squamous cell, and Merkel cell carcinoma) have been reported in patients who have received ruxolitinib. Periodic skin examinations should be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: May require initial dosage reduction. In patients with myelofibrosis, avoid use if platelets &lt;50,000/mm<sup>3</sup> and with hepatic impairment (any degree).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: May require initial dosage reduction. Avoid use in patients with ESRD not requiring dialysis; in patients with myelofibrosis, avoid use if platelets &lt;50,000/mm<sup>3</sup> and with moderate to severe renal impairment. Ruxolitinib is not removed by dialysis; however, some active metabolites may be removed. On dialysis days, patients are advised to take their dose following dialysis sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Discontinue treatment in myelofibrosis patients after 6 months if no reduction in spleen size or no improvement in symptoms. Consider gradually tapering off if discontinuing for reasons other than thrombocytopenia. Within ~1 week after discontinuation, symptoms of myelofibrosis generally return to pretreatment levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal syndrome: Acute relapse of myelofibrosis symptoms (eg, fever, respiratory distress, hypotension, DIC, multiorgan failure), splenomegaly, worsening cytopenias, hemodynamic compensation, and septic shock-like syndrome have been reported with treatment tapering or discontinuation (Tefferi 2011). Symptoms generally return over approximately 1 week. Evaluate and treat any intercurrent illness and consider restarting or increasing dose. Consider gradually tapering off if discontinuing for reasons other than thrombocytopenia or neutropenia. Patients should not interrupt/discontinue treatment without consulting healthcare provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382922\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382921\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17096&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: Ruxolitinib may enhance the bradycardic effect of Bradycardia-Causing Agents.  Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ruxolitinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ruxolitinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ruxolitinib. Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Ruxolitinib. Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Ruxolitinib. Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382584\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase the effects of ruxolitinib. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382563\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Use of ruxolitinib in pregnant women is not recommended; other agents are preferred (Gerds 2017; Kiladjian 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382565\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ruxolitinib is present in breast milk. Due to the potential for serious adverse reactions, discontinue breastfeeding during ruxolitinib treatment and for 2 weeks after the final dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382601\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice (may increase the effects of ruxolitinib).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382604\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC (baseline, every 2 to 4 weeks until dose stabilized, then as clinically indicated), lipid parameters (8 to 12 weeks after ruxolitinib initiation and as appropriate thereafter), renal function, hepatic function. Monitor hepatitis B viral load (HBV-DNA titer) in patients with chronic hepatitis B infection. Perform periodic skin examinations monitor for signs/symptoms of infection; Tuberculin skin test (prior to initiation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382587\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Kinase inhibitor which selectively inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2.  JAK1 and JAK2 mediate signaling of cytokine and growth factors responsible for hematopoiesis and immune function; JAK mediated signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors which leads to modulation of gene expression. In myelofibrosis and polycythemia vera, JAK1/2 activity is dysregulated; ruxolitinib modulates the affected JAK1/2 activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382589\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Myelofibrosis: 72 L; Polycythemia vera: 75 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~97%; primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, primarily via CYP3A4 (and minimally CYP2C9); forms active metabolites responsible for 20% to 50% of activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Ruxolitinib: ~3 hours (hepatic impairment: 4.1 to 5 hours); Ruxolitinib + metabolites: ~5.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Within 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (74%, &lt;1% as unchanged drug); feces (22%, &lt;1% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322922\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Jakafi Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $14,688.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $14,688.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $14,688.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $14,688.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $14,688.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059497\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dzhakavi (UA);</li>\n      <li>Jakavi (AE, AR, AT, AU, BE, BR, CH, CL, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, IL, IS, JO, JP, KR, KW, LT, LU, LV, MT, NL, NO, NZ, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cervantes F, Vannucchi AM, Kiladjian JJ, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i>. 2013;122(25):4047-4053.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/24174625/pubmed\" target=\"_blank\" id=\"24174625\">24174625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen X, Williams WV, Sandor V, Yeleswaram S. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). <i>J Clin Pharmacol</i>. 2013;53(7):721-730.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/23677817/pubmed\" target=\"_blank\" id=\"23677817\">23677817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerds AT, Dao KH. Polycythemia vera management and challenges in the community health setting. <i>Oncology</i>. 2017;92(4):179-189. doi: 10.1159/000454953.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/28095380/pubmed\" target=\"_blank\" id=\"28095380\">28095380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harrison C, Kiladjian JJ, Al-Ali HK, et al, &ldquo;JAK Inhibition With Ruxolitinib versus Best Available Therapy for Myelofibrosis,&rdquo; <i>N Engl J Med</i>, 2012, 366(9):787-98. doi: 10.1002/jcph.102<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/22375970/pubmed\" target=\"_blank\" id=\"22375970\">22375970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jakafi (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jakavi (ruxolitinib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kiladjian JJ. Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms. <i>Am Soc Clin Oncol Educ Book</i>. 2015:389-396. doi: 10.14694/EdBook_AM.2015.35.e389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/25993201/pubmed\" target=\"_blank\" id=\"25993201\">25993201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. <i>J Clin Oncol</i>. 2013;31(10):1285-1292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/23423753/pubmed\" target=\"_blank\" id=\"23423753\">23423753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mesa RA, Kantarjian H, Tefferi A, et al, &ldquo;Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement: Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical Trial,&rdquo; <i>Cancer</i>, 2011, 117(21):4869-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/21480207/pubmed\" target=\"_blank\" id=\"21480207\">21480207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. <i>J Clin Pharmacol</i>. 2012;52(6):809-818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/21602517/pubmed\" target=\"_blank\" id=\"21602517\">21602517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shilling AD, Nedza FM, Emm T, et al, &ldquo;Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans,&rdquo; <i>Drug Metab Dispos</i>, 2010, 38(11):2023-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/20699411/pubmed\" target=\"_blank\" id=\"20699411\">20699411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tefferi A and Pardanani A, &ldquo;Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis,&rdquo; <i>Mayo Clin Proc</i>, 2011, 86(12):1188-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/22034658/pubmed\" target=\"_blank\" id=\"22034658\">22034658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tefferi A, Litzow MR, and Pardanani A, Long-Term Outcome of Treatment With Ruxolitinib in Myelofibrosis,&rdquo; <i>N Engl J Med</i>, 2011, 365(15):1455-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/21995409/pubmed\" target=\"_blank\" id=\"21995409\">21995409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. <i>N Engl J Med</i>. 2015;372(5):426-435.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/25629741/pubmed\" target=\"_blank\" id=\"25629741\">25629741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. <i>Blood</i>. 2012;120(6):1202-1209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/22718840/pubmed\" target=\"_blank\" id=\"22718840\">22718840</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verstovsek S, Kantarjian H, Mesa RA, et al, &ldquo;Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis,&rdquo; <i>N Engl J Med</i>, 2010, 363(12):1117-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/20843246/pubmed\" target=\"_blank\" id=\"20843246\">20843246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verstovsek S, Mesa RA, Gotlib J, et al, &ldquo;A Double Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis,&rdquo; <i>N Engl J Med</i>, 2012, 366(9):799-807.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/22375971/pubmed\" target=\"_blank\" id=\"22375971\">22375971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. <i>Cancer</i>. 2014;120(4):513-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ruxolitinib-drug-information/abstract-text/24258498/pubmed\" target=\"_blank\" id=\"24258498\">24258498</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17096 Version 146.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13376660\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14732981\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13374759\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13382600\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13382599\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13382598\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F13382628\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13375647\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F13382561\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F13382560\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13382602\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132643\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13374761\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13382558\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13382579\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13382566\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13382567\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13382922\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13382921\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13382584\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13382563\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13382565\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F13382601\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13382604\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13382587\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13382589\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322922\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059497\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/17096|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ruxolitinib-patient-drug-information\" class=\"drug drug_patient\">Ruxolitinib: Patient drug information \t</a></li></ul></div></div>","javascript":null}